Abstract 2312
Background
MicroRNAs (miRs) are small non-coding RNAs. Circulating miRs in plasma are deregulated in patients with metastatic colorectal cancer (mCRC). The aim was to find prognostic circulating miRs for overall survival (OS) in patients with mCRC treated with chemotherapy and cetuximab.
Methods
A prospective biomarker study was conducted. A full plasma miR-panel was tested with TaqMan Human MicroRNA assay in 151 patients treated with 3rd line irinotecan and cetuximab (Discovery cohort, Biweekly study). Significant miRs were validated with Fluidigm arrays, in 95 patients, treated with 1st line chemotherapy and cetuximab (Validation cohort, NORDIC-7.5 study1). Cox regression analysis was conducted, and multivariate analyses performed with adjustment for sidedness, number of metastatic sites, RAS/BRAF mutation status, age and performance status. Consecutive samples after 3 months of treatment were available for 117 and 86 patients in the discovery and validation cohorts, respectively.
Results
Baseline high expression of miR-1247 in the discovery and validation cohorts, was significantly associated with short OS (hazard ratio [HR]) = 2.33, p = 0.0005) based on the multivariate analysis in the validation cohort. High miR-1290 expression after 3 months was prognostic for short progression free-survival (HR = 1.57, p = 0.0465) in both cohorts. In both cohorts, we found a statistically significant decrease in, miR-1290 (p = 0.0051), miR-200b (p = 0.036), and miR-375 (p = 0.00005), from baseline to 3 month-sample, in patients with partial/complete (n = 78) response compared to patients with progressive disease (n = 72).
Conclusions
High expression of miR-1247 was prognostic for short OS in the multivariate analysis in a discovery and validation cohort of patients treated with chemotherapy and cetuximab in both first and third line. A decrease in miR-1247 and miR-1290 during treatment was associated with favorable response. 1Pfeiffer et al, Clin Colorectal Cancer 2015.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jakob Vasehus Scho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3716 - Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma
Presenter: Naru Kim
Session: Poster Display session 2
Resources:
Abstract
3947 - Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
Presenter: Teresa Macarulla
Session: Poster Display session 2
Resources:
Abstract
2880 - Expression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection.
Presenter: Mariko Kamiya
Session: Poster Display session 2
Resources:
Abstract
5029 - POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract
4730 - Diagnostic Value of Digital Multiplexed Detection of Single Nucleotide Variants in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasound Fine-Needle Aspiration
Presenter: Irina Cazacu
Session: Poster Display session 2
Resources:
Abstract
3303 - Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Presenter: Esther Pijnappel
Session: Poster Display session 2
Resources:
Abstract
2009 - Efficacy of platinum-containing chemotherapy and prognosis of pancreatic cancer patients with homologous recombination deficiency: meta-analysis of published clinical studies
Presenter: Elizeveta Polyanskaya
Session: Poster Display session 2
Resources:
Abstract
2164 - Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
Presenter: Valeria Merz
Session: Poster Display session 2
Resources:
Abstract
2529 - A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma
Presenter: Jie Hua
Session: Poster Display session 2
Resources:
Abstract
4947 - Pre-treatment serum 25-hydroxyvitamin D levels and survival in a Danish cohort of patients with pancreatic cancer
Presenter: Louise Rasmussen
Session: Poster Display session 2
Resources:
Abstract